IDEAYA Biosciences

IDEAYA Biosciences is a precision medicine company focused on hard-to-treat cancers. It describes an R&D engine built to deliver first-in-class targeted therapies and rational combinations for molecularly defined cancers, with pipeline priorities including PKC inhibition in uveal melanoma, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition. Its lead investigational candidate, darovasertib, is in late-stage and registrational trials across all stages of uveal melanoma, with an anticipated regulatory submission for metastatic uveal melanoma in the second half of 2026. Yujiro S. Hata is Founder, Chairman and Chief Executive Officer.

IDEAYA Biosciences presents itself as a precision medicine company working on hard-to-treat cancers. It states that it is uncovering hidden vulnerabilities behind these diseases and developing innovative targeted approaches to treat them, with the ambition to deliver transformative therapies to patients who need them most. The company describes an established R&D engine built to deliver first-in-class targeted therapies and rational combinations to treat molecularly defined cancers, with pipeline priorities including PKC inhibition in uveal melanoma, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition. Its lead investigational candidate, darovasertib, is described as having the potential to be the first targeted therapy for all stages of uveal melanoma and is currently in late-stage and registrational trials across all stages of UM, with anticipated regulatory submission for metastatic uveal melanoma in the second half of 2026. The company also states that it is advancing a deep pipeline of clinical-stage precision medicines for multiple potential solid tumor indications.

Precision medicine company targeting cancer's key drivers with first-in-class targeted therapies and rational combinations for molecularly defined cancers.

• Darovasertib

  Lead investigational candidate described as having the potential to be the first targeted therapy for all stages of uveal melanoma, currently in late-stage and registrational trials across all stages of UM, with anticipated regulatory submission for metastatic uveal melanoma in the second half of 2026.

• 2022.04.06

  Reported2022.04.06

  IDEAYA Biosciences appoints Catherine Mackey to its board[5]IDEAYA Biosciences任命Catherine Mackey为董事会成员prnewswire.com

  IDEAYA Biosciences announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors.

• 2020.09.24

  Reported2020.09.24

  IDEAYA and Pfizer expanded clinical trial collaboration and supply agreement[6]IDEAYA与Pfizer扩大临床试验合作及供应协议finanznachrichten.de

  IDEAYA announced that it had expanded its clinical trial collaboration and supply agreement with Pfizer for an IDEAYA-sponsored combination study of IDE196 and crizotinib. IDEAYA will sponsor the study and Pfizer will supply crizotinib.

• 2020.08.04

  Reported2020.08.04

  IDEAYA-GSK synthetic lethality partnership takes effect[7]IDEAYA与GSK的合成致死合作生效prnewswire.com

  IDEAYA announced that its Collaboration, Option and License Agreement with GSK became effective following HSR clearance; IDEAYA received a $100 million upfront payment.

• 2020.08.04

  Reported2020.08.04

  Glaxo Group closes $20 million IDEAYA equity investment[7]IDEAYA与GSK的合成致死合作生效prnewswire.com

  IDEAYA announced the closing of a private placement in which Glaxo Group purchased 1,333,333 IDEAYA common shares at $15 per share, providing IDEAYA approximately $20 million in proceeds.

• 2020.06.17

  Reported2020.06.18

  IDEAYA announces pricing of public stock offering[8]IDEAYA宣布普通股公开发行定价prnewswire.com

  IDEAYA announced the pricing of an underwritten public offering of 6,666,667 common shares at $15.00 per share. The offering was expected to close on or about June 22, 2020, subject to customary conditions.

• 2019.10.08

  Reported2019.10.08

  IDEAYA and Foundation Medicine enter genomic profiling collaboration[9]IDEAYA与Foundation Medicine开展基因组分析合作prnewswire.com

  IDEAYA Biosciences entered into a collaboration with Foundation Medicine to support IDEAYA's tissue-type agnostic strategy, including genomic profiling of tumor samples from its ongoing Phase 1/2 clinical trial and analyses of Foundation Medicine's FoundationCORE database.

Read more

1. 1Redefining what’s possible with precision medicine | IDEAYA Biosciencesideayabio.com
2. 2About IDEAYA Biosciences | Precision Medicineideayabio.com
3. 3Clinical Trials in Precision Oncology | IDEAYAideayabio.com
4. 4Management Team | IDEAYA Biosciencesideayabio.com
5. 5IDEAYA Biosciences任命Catherine Mackey为董事会成员prnewswire.com
6. 6IDEAYA与Pfizer扩大临床试验合作及供应协议finanznachrichten.de
7. 7IDEAYA与GSK的合成致死合作生效prnewswire.com
8. 8IDEAYA宣布普通股公开发行定价prnewswire.com
9. 9IDEAYA与Foundation Medicine开展基因组分析合作prnewswire.com
10. 10IDEAYA Announces Pricing of Public Offering of Common Stockprnewswire.com